CVS Health (NYSE:CVS) Upgraded to Buy at Wall Street Zen

CVS Health (NYSE:CVS) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Sunday.

Several other research firms have also recently commented on CVS. Royal Bank Of Canada boosted their price target on CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Barclays raised their price objective on CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a report on Thursday, June 11th. Wolfe Research cut their target price on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Finally, Wells Fargo & Company increased their target price on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.68.

CVS Health Price Performance

CVS opened at $98.26 on Friday. CVS Health has a twelve month low of $58.50 and a twelve month high of $102.77. The firm has a market cap of $125.38 billion, a price-to-earnings ratio of 43.29, a PEG ratio of 0.96 and a beta of 0.62. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The company has a fifty day simple moving average of $89.31 and a 200 day simple moving average of $81.48.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts expect that CVS Health will post 7.44 EPS for the current fiscal year.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On CVS Health

A number of institutional investors have recently modified their holdings of the business. Pacer Advisors Inc. lifted its holdings in CVS Health by 1,020.7% in the first quarter. Pacer Advisors Inc. now owns 4,845,221 shares of the pharmacy operator’s stock worth $347,984,000 after acquiring an additional 4,412,882 shares during the last quarter. Pine Valley Investments Ltd Liability Co grew its holdings in shares of CVS Health by 4.2% during the first quarter. Pine Valley Investments Ltd Liability Co now owns 18,820 shares of the pharmacy operator’s stock valued at $1,352,000 after purchasing an additional 763 shares during the last quarter. DV Trading LLC grew its holdings in shares of CVS Health by 213.2% during the first quarter. DV Trading LLC now owns 3,000 shares of the pharmacy operator’s stock valued at $215,000 after purchasing an additional 2,042 shares during the last quarter. Parallel Advisors LLC raised its position in shares of CVS Health by 7.5% during the 1st quarter. Parallel Advisors LLC now owns 12,478 shares of the pharmacy operator’s stock worth $896,000 after purchasing an additional 869 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in shares of CVS Health by 21.6% in the 1st quarter. NewEdge Advisors LLC now owns 130,922 shares of the pharmacy operator’s stock worth $9,403,000 after purchasing an additional 23,233 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.